Review
Oncology
Juan-Yan Liao, Shuang Zhang
Summary: Cancer immunotherapy, particularly the combination of personalized cancer vaccines with immune checkpoint inhibitors, shows promise in enhancing antitumor efficacy with good safety profile, indicating a potential future direction in cancer treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Xiaoling Gong, Yahui Zhu, Qianning Zhang, Xin Qiu, Changchang Lu, Fan Tong, Qiaoli Wang, Weiwei Kong, Haihui Zhou, Baorui Liu, Yujie Zhou, Juan Du
Summary: This study investigates the efficacy and safety of immune checkpoint inhibitors (ICIs) in Chinese patients with advanced pancreatic cancer (APC). The results show that combined radiotherapy leads to longer overall survival (OS) and progression-free survival (PFS), as well as higher objective response rate (ORR) and disease control rate (DCR). Patients who received a combination of chemotherapy also had longer OS and PFS compared to those combined with targeted therapy. ICIs as a first-line treatment may result in better survival outcomes. Patients with a high tumor mutational burden (TMB) had longer OS, while adverse events (AEs) were considered tolerable. The combination therapy of ICIs, especially with chemotherapy and radiotherapy, proved to be safe and effective for treating APC.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Review
Oncology
Alberto Carretero-Gonzalez, Irene Otero, David Lora, Lucia Carril-Ajuria, Daniel Castellano, Guillermo de Velasco
Summary: The study examines the benefits and risks of adding ICIs to standard of care, finding that adding ICIs can prolong survival with no early detrimental effect. Results show that ICIs arm has better PFS, OS, and ORR compared to SOC, although also associated with a slight increase in high-grade adverse events.
Review
Pharmacology & Pharmacy
Giandomenico Roviello, Luigi Francesco Iannone, Melissa Bersanelli, Enrico Mini, Martina Catalano
Summary: Immunotherapy has revolutionized cancer treatment, but reliable biomarkers for predicting treatment response are still unknown. Recent studies suggest that the gut microbiota may play a role in modulating the efficacy and toxicity of immunotherapy drugs.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Biotechnology & Applied Microbiology
Zhitao Chen, Yahui He, Chenchen Ding, Jun Chen, Yangjun Gu, Min Xiao, Qiyong Li
Summary: Combining GnP with anti-PD-1 antibodies shows promising results as a potential treatment option for advanced pancreatic cancer, with a median overall survival of 16.4 months and a median progression-free survival of 6.4 months. The study also found significant impacts of Eastern Cooperative Oncology Group performance status and treatment cycles on patient survival.
ONCOTARGETS AND THERAPY
(2023)
Review
Pharmacology & Pharmacy
Yun Tian, Zhenzhu Liu, Jianbo Wang, Linan Li, Fuli Wang, Zheng Zhu, Xuejian Wang
Summary: Urologic cancers, such as kidney, bladder, and prostate cancer, have a growing incidence and cause a significant number of deaths worldwide. Immunotherapy, including immunological checkpoint blockade, non-specific activation of the immune system, adoptive cell therapy, and tumor vaccine, shows promise but faces challenges in terms of toxicities and response rates. Nanomaterial-based platforms offer solutions by combining nanotechnology with immunotherapy, leading to precision medicine, improved efficacy, and reduced toxicities in urologic cancer treatment.
Review
Immunology
Gustavo C. L. Gossling, David B. Zhen, Venu G. Pillarisetty, E. Gabriela Chiorean
Summary: Despite the role of immune systems on progression and survival, immune checkpoint inhibitors (ICI) have not been effective in treating pancreatic ductal adenocarcinoma (PDA). However, recent pathways have identified new targets and generated promising clinical investigations for promoting an effective immune response in PDA.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Qinghua Wu, Yang Chen, Qing Li, Junmeng Chen, Junfeng Mo, Ming Jin, Qianzhan Yang, Loris Rizzello, Xiaohe Tian, Lei Luo
Summary: This study investigates the timing of intervention with immune checkpoint inhibitors (ICI) after photodynamic therapy (PDT) and its impact on tumor efficacy. A tumor-targeting nanomedicine encapsulating indocyanine green is prepared, and ICI is administered 5 days after PDT. The optimal combination significantly suppresses tumor growth and eliminates metastasis. This research provides theoretical guidance for enhancing immune checkpoint blockade therapy (ICBT) through intervention timing.
Article
Oncology
Jnaneshwari Pradeep, Thin Thin Win, Saint Nway Aye, Chandrashekhar T. Sreeramareddy
Summary: The combination therapy of nivolumab and ipilimumab showed significantly prolonged overall survival and progression-free survival in treating advanced MM compared to single therapy, but monotherapy had a lower incidence of treatment-related adverse events, indicating a higher safety profile.
Article
Urology & Nephrology
Naoka Murakami, Patrick Mulvaney, Melissa Danesh, Ala Abudayyeh, Adi Diab, Noha Abdel-Wahab, Maen Abdelrahim, Pascale Khairallah, Shayan Shirazian, Aleksandra Kukla, Itunu O. Owoyemi, Tarek Alhamad, Samir Husami, Madhav Menon, Andrew Santeusanio, Christopher D. Blosser, Sandra Carias Zuniga, Maria Jose Soler, Francesc Moreso, Zain Mithani, David Ortiz-Melo, Edgar A. Jaimes, Victoria Gutgarts, Erik Lum, Gabriel M. Danovitch, Francesca Cardarelli, Reed E. Drews, Claude Bassil, Jennifer L. Swank, Scott Westphal, Roslyn B. Mannon, Keisuke Shirai, Abhijat Kitchlu, Song Ong, Shana M. Machado, Suraj S. Mothi, Patrick A. Ott, Osama Rahma, F. Stephen Hodi, Meghan E. Sise, Shruti Gupta, David E. Leaf, Craig E. Devoe, Rimda Wanchoo, Vinay V. Nair, Chrysalyne D. Schmults, Glenn J. Hanna, Ben Sprangers, Leonardo V. Riella, Kenar D. Jhaveri
Summary: Immune checkpoint inhibitors pose a high risk of acute rejection in kidney transplant patients but may lead to improved cancer outcomes. Prospective studies are needed to determine optimal immunosuppression strategies to improve patient outcomes.
KIDNEY INTERNATIONAL
(2021)
Review
Pharmacology & Pharmacy
Pavlos Msaouel, Giannicola Genovese, Jianjun Gao, Suvajit Sen, Nizar M. Tannir
Summary: Immune checkpoint inhibitors have shown promise in cancer treatment but are not always long-lasting and effective for all patients. Targeting TAM kinases with tyrosine kinase inhibitors may enhance the efficacy of immune checkpoint blockade, but whether selective targeting of each TAM receptor or multi-receptor TAM inhibitors are more effective remains to be determined. Triple inhibition of all TAM receptors may lead to increased risk of adverse events, and clinical trial designs should focus on determining the synergistic effects of combining TAM inhibition with immune checkpoint blockade through high-resolution clinical endpoints and proper control arms.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2021)
Review
Oncology
Valentina Zanuso, Angelo Pirozzi, Rita Balsano, Tiziana Pressiani, Lorenza Rimassa
Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Immunotherapy combinations have become the standard first-line treatment, improving overall survival and quality of life. However, predictive biomarkers for patient selection and optimal subsequent therapy for treatment failure are still lacking.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2023)
Review
Oncology
Jing Wu, Rong Deng, Tingting Ni, Qin Zhong, Fei Tang, Yan Li, Yu Zhang
Summary: This study evaluated the safety and efficacy of combining ICIs with RT/CRT for EC patients, showing promising results in terms of one- and two-year overall survival rates but with a higher incidence of grade 3-5 adverse reactions. Additional large randomized studies are required to confirm these findings.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Lingyue Liu, Xing Huang, Fukang Shi, Jinyuan Song, Chengxiang Guo, Jiaqi Yang, Tingbo Liang, Xueli Bai
Summary: Pancreatic cancer has a high mortality rate and immunotherapy with anti-PD-(L)1 has limited efficacy. This review explores the combination of chemotherapy, radiotherapy, targeted therapy, and immunotherapy with anti-PD-(L)1 in pancreatic cancer treatment. It also suggests future directions for optimizing combination therapy.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Fei Yang, Jun Yang, Wei Xiang, Bin-Yan Zhong, Wan-Ci Li, Jian Shen, Shuai Zhang, Yu Yin, Hong-Peng Sun, Wan-Sheng Wang, Xiao-Li Zhu
Summary: This study explores the safety and efficacy of TACE in combination with ICIs and TKIs for the treatment of uHCC. The results show that this combination therapy has an acceptable safety profile and considerable efficacy in patients with HCC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Respiratory System
Erin M. Corsini, Jinliang Wang, Chia-Chin Wu, Junya Fujimoto, Marcelo Negrao, Runzhe Chen, Kelly Quek, Kyle G. Mitchell, Chi-Wan B. Chow, Latasha Little, Curtis Gumbs, Xingzhi Song, Carmen Behrens, Arlene M. Correa, Mara B. Antonoff, Stephen G. Swisher, John Heymach, Jianhua Zhang, Ignacio I. Wistuba, P. Andrew Futreal, Boris Sepesi, Jianjun Zhang
JOURNAL OF THORACIC DISEASE
(2020)
Article
Multidisciplinary Sciences
Pengfei Cui, Ruixin Li, Ziwei Huang, Zhaozhen Wu, Haitao Tao, Sujie Zhang, Yi Hu
SCIENTIFIC REPORTS
(2020)
Article
Immunology
Zhibo Zhang, Fang Yuan, Runzhe Chen, Ye Li, Junxun Ma, Xiang Yan, Lijie Wang, Fan Zhang, Haitao Tao, Dong Guo, Zhiyue Huang, Sujie Zhang, Xiaoyan Li, Xiaoyu Zhi, Xiangwei Ge, Yi Hu, Jinliang Wang
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Oncology
Ye Li, Zhibo Zhang, Yi Hu, Xiang Yan, Qi Song, Guoqiang Wang, Runzhe Chen, Shunchang Jiao, Jinliang Wang
FRONTIERS IN ONCOLOGY
(2020)
Article
Oncology
Qi Xiong, Ziwei Huang, Lingli Xin, Boyu Qin, Xiao Zhao, Jing Zhang, Weiwei Shi, Bo Yang, Guoqing Zhang, Yi Hu
Summary: In small cell lung cancer patients, NLR at 6 weeks after treatment initiation appears to be a biomarker of response to anti-PD-1/PD-L1 antibody treatment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Di Huang, Pengfei Cui, Ziwei Huang, Zhaozhen Wu, Haitao Tao, Sujie Zhang, Rong Xiang, Yi Hu
Summary: This retrospective study evaluated the efficacy and safety of anti-PD-1/L1 plus anti-angiogenesis therapy in patients with advanced lung adenocarcinoma. Results showed that compared to anti-PD-1/L1 monotherapy, the combination therapy significantly improved disease control rate, progression-free survival and overall survival in patients who had failed first-line or later treatment. Further prospective studies are needed to validate these findings.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Zhaozhen Wu, Haitao Tao, Sujie Zhang, Xiao Wang, Junxun Ma, Ruixin Li, Zhefeng Liu, Jinliang Wang, Pengfei Cui, Shixue Chen, Huang Di, Ziwei Huang, Xuan Zheng, Yi Hu
Summary: The combination of PARP inhibitors and anti-PD-1 has shown promising efficacy and safety in advanced solid tumors, with BRCA1/2 mutation potentially serving as a biomarker. The study revealed potential resistant mechanisms and the importance of factors like LDH levels in predicting treatment response and outcomes.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Tingting Liu, Jiang Wang, Tao Li, Pengfei Cui, Baicun Hou, Chunxiao Zhuang, Ge Wei, Sujie Zhang, Hongxia Li, Yi Hu
Summary: The study found that NMPs and PMPs are associated with disease progression in advanced NSCLC. The predictive model established combining NMPs, PMPs, and NLR can screen out 80.8% of patients with progressive disease.
Article
Oncology
Ziwei Huang, Qi Xiong, Zhi Cui, Haitao Tao, Sujie Zhang, Lijie Wang, Pengfei Cui, Shixue Chen, Di Huang, Bo Yang, Yi Hu
Summary: The study demonstrated that crizotinib plus bevacizumab showed benefit in treating naive ALK rearrangement NSCLC patients, with relatively tolerable toxicity.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Article
Medicine, Research & Experimental
Zhenxin Wang, Guoqing Zhang, Zhongcheng Li, Jin Li, Hongbo Ma, Ailian Hei, Shunchang Jiao, Yi Hu, Shengjie Sun, Liangliang Wu, Ji Zhou, Yu Wang, Ellen He, Sven Skog
Summary: The prospective study evaluated the prognostic value of serum thymidine kinase 1 concentration in non-small-cell lung carcinoma patients. Results showed that elevated STK1p values were associated with worse overall survival, especially in early/middle stages, and STK1p could be an independent prognostic factor for favorable overall survival in NSCLC patients.
Article
Oncology
Zhibo Zhang, Fan Zhang, Fang Yuan, Ye Li, Junxun Ma, Qiuxiang Ou, Zhefeng Liu, Bo Yang, Lijie Wang, Haitao Tao, Sujie Zhang, Xiaoyan Li, Xiaoyu Zhi, Xiangwei Ge, Hua Bao, Xue Wu, Yi Hu, Jinliang Wang
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2020)
Article
Oncology
Shixue Chen, Ziwei Huang, Wangping Jia, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Lijie Wang, Pengfei Cui, Zhibo Zhang, Di Huang, Zhaozhen Wu, Xuan Zheng, Yi Hu
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2020)
Article
Oncology
Fan Zhang, Di Huang, Lei Zhao, Tao Li, Sujie Zhang, Guoqing Zhang, Fang Yuan, Jie Zhang, Yuzi Zhang, Zhengyi Zhao, Longgang Cui, Jing Zhao, Guoqiang Wang, Shangli Cai, Yuezong Bai, Jinliang Wang, Yi Hu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2020)
Article
Oncology
Pengfei Cui, Di Huang, Zhaozhen Wu, Haitao Tao, Sujie Zhana, Junxun Ma, Zhefeng Liu, Jinliang Wang, Ziwei Huang, Shixue Chen, Xuan Zheng, Yi Hu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2020)